Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dyax Kalbitor Is Third To Market For HAE, But First For All Acute Attacks

Executive Summary

Overcoming an FDA advisory committee that expressed doubts about efficacy and potential hypersensitivity reactions and a "complete response" letter asking for a Risk Evaluation and Mitigation Strategy, Dyax won approval for Kalbitor (ecallantide) Nov. 27 to treat acute attacks of hereditary angioedema in patients 16 and older
Advertisement

Related Content

Different Endpoints Drive HAE Drugs On Road To Approval
ViroPharma Could Manufacture Cinryze "At Risk" Starting Next Year
FDA Advertising Enforcers Have Little Patience For "Well Tolerated" Drug Claims
Advisory Committee Discussions Will Be Key Tool In Developing REMS
Berinert Claims Another Part Of The HAE Orphan Market, But May Leave Room
Berinert Claims Another Part Of The HAE Orphan Market, But May Leave Room
ViroPharma Gets Good News And Bad News On Cinryze From FDA
Dyax Receives “Complete Response” For HAE Drug; REMS Will Be Required
Dyax’s Acute HAE Candidate Faces Efficacy And Risk Hurdles At Panel Review
Cinryze Launch Plans Bear Hallmarks Of Successful Orphan Strategies

Topics

Advertisement
UsernamePublicRestriction

Register

PS051735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel